APA (7th ed.) Citation

Shao, Y., Chen, B., Ou, D., Lin, Z., Hsu, C., Wang, M., . . . Hsu, C. (2017). Lenalidomide as second‐line therapy for advanced hepatocellular carcinoma: Exploration of biomarkers for treatment efficacy. Alimentary pharmacology & therapeutics, 46(8), 722-730. https://doi.org/10.1111/apt.14270

Chicago Style (17th ed.) Citation

Shao, Y.‐Y, B.‐B Chen, D.‐L Ou, Z.‐Z Lin, C.‐H Hsu, M.‐J Wang, A.‐L Cheng, and C. Hsu. "Lenalidomide as Second‐line Therapy for Advanced Hepatocellular Carcinoma: Exploration of Biomarkers for Treatment Efficacy." Alimentary Pharmacology & Therapeutics 46, no. 8 (2017): 722-730. https://doi.org/10.1111/apt.14270.

MLA (9th ed.) Citation

Shao, Y.‐Y, et al. "Lenalidomide as Second‐line Therapy for Advanced Hepatocellular Carcinoma: Exploration of Biomarkers for Treatment Efficacy." Alimentary Pharmacology & Therapeutics, vol. 46, no. 8, 2017, pp. 722-730, https://doi.org/10.1111/apt.14270.